Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole for Metabolic Syndrome in Schizophrenia and Bipolar Disorder
NCT00224822Phase 4Completed
- Sponsor
- New Mexico VA Healthcare System
- Start
- Mar 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aripiprazole in schizophrenia, schizoaffective disorder and bipolar disorder (BD), sponsored by New Mexico VA Healthcare System. Primary endpoints: Weight gain/Body Mass Index, Brief Psychiatric Rating Scale and 1 more. Started Mar 2004; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophreniaschizoaffective disorderbipolar disorder (BD)
Beyond the preview
Go deeper on NCT00224822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00224822.